The Absorption and Metabolism of Seaweed Polyphenols in Humans

Seaweed Derived Anti-inflammatory Agents and Antioxidants

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02496806

Acronym

SWAFAX

Enrollment

Registered

2015-07-14

Start date

2011-05-31

Completion date

2012-12-31

Last updated

2015-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Polyphenols, Absorption, Metabolism, Phlorotannins, Seaweeds

Brief summary

Brown seaweeds are a rich source of phlorotannins, a characteristic class of polyphenols which are unique to seaweeds of this type and can comprise 5 to 15 % of the dried weight. Unlike other classes of polyphenols, there is a lack of knowledge regarding phlorotannins and their bioavailability and bioactivity. The purpose of this study is to investigate the absorption and metabolism of seaweed polyphenols in humans. As part of an EC project (SWAFAX), an acute clinical intervention will be conducted to investigate the metabolism/ bioavailability of brown seaweed phlorotannins. Urine and plasma samples from 24 healthy volunteers that consumed a seaweed capsule containing polyphenols will be collected before and after the intervention. Data emanating from this project will provide strong scientific evidence for bioavailability and health promoting activity of a seaweed polyphenol extract in human volunteers.

Interventions

DIETARY_SUPPLEMENTSeaweed extract

Treatment capsule containing seaweed extract (treatment)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Good general health * Body Mass Index of 18-30 Kg/m2

Exclusion criteria

* Inability to swallow capsules * Smoking * Alcohol intake of \>21 units/wk * Blood pressure \> 150/90 mmHg * Any dietary restrictions or weight reducing diet * Vegetarian * Heamoglobin levels\< 125 g/l for male, \< 110 g/l for female, * Gamma GT levels \> 80 IU/l * Cholesterol levels \> 6.5 mmol/l * Myocardial infarction or stroke in the previous 12 months * Gastrointestinal disease or chronic gastrointestinal disorders * Reproductive disorder * Blood-clotting disorder * Metabolic disorders * Lipid-modifying medication * Blood clotting mdication * Antibiotic medication in previous 3 months before study * Lactation * Pregnancy * Females of childbearing potential and not using effective contraceptive precautions

Design outcomes

Primary

Measure	Time frame
Seaweed polyphenol metabolites in urine	24 hours
Seaweed polyphenol metabolites in plasma	24 hours

Secondary

Measure	Time frame
Citokine levels in plasma	24 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026